Argentina’s National Administration of Medicines, Food and Medical Technology (ANMAT) has revoked the operating licenses of 60 laboratories and pharmacies across the country, effective this Friday, February 20, 2026. The action stems from expired certifications required for the interjurisdictional transit of medications and medicinal specialties. This enforcement action underscores ANMAT’s commitment to maintaining the integrity of the pharmaceutical supply chain and ensuring public health safety.
The decision is formalized in Disposición 694/2026, published today in the Official Gazette, and signed by ANMAT’s director, Luis Eduardo Fontana. The measure targets establishments that failed to renew their certificates of compliance with good distribution practices for medications, a critical component of ensuring product quality and traceability.
Ensuring Safe Medication Transit
ANMAT’s actions are rooted in Argentina’s legal framework governing the pharmaceutical industry. Law No. 16.463 establishes that the production, distribution, and sale of drugs require authorization and oversight by the health authority. Decrees 1490/92 and 1299/97 further detail the regulatory requirements. The current enforcement builds upon previous ANMAT provisions, specifically Dispositions 3475/05 and 7038/15, which outlined the specific requirements for pharmacies engaged in interjurisdictional trade.
The focus on expired certifications highlights a proactive approach to identifying and addressing potential vulnerabilities in the distribution network. Expired certificates indicate a lapse in the regular audits and inspections designed to verify adherence to good distribution practices. These practices are essential for maintaining the quality, safety, and efficacy of medications throughout their journey from manufacturer to patient.
Impact on Pharmaceutical Distribution
The revocation of licenses will likely disrupt the supply of medications in the affected regions, at least temporarily. Pharmacies and laboratories without valid certifications are prohibited from transporting medications across provincial boundaries. This could lead to localized shortages, particularly for specialized medications or those sourced from distant locations. However, ANMAT’s action is intended to prevent the circulation of potentially compromised products, prioritizing long-term public health over short-term convenience.
According to reporting from Portal COFA, the initial number of affected pharmacies was 61, but the official ANMAT disposition lists 60. The discrepancy has not been officially clarified.
What Happens Next?
The affected laboratories and pharmacies will necessitate to rectify their certification status to resume interjurisdictional transit. This involves undergoing the necessary inspections and audits to demonstrate compliance with current good distribution practices. ANMAT has not specified a timeline for reinstatement, but it is expected that establishments will be required to address any deficiencies identified during the inspection process before their licenses can be restored.
For consumers, the immediate impact may be limited, but it’s important to be aware of potential disruptions in medication availability. Patients with chronic conditions or those requiring specific medications should consult with their pharmacists to ensure a continued supply. ANMAT has not issued specific guidance for patients, but it is likely to provide updates as the situation evolves.
ANMAT’s Ongoing Regulatory Role
This action is part of a broader effort by ANMAT to strengthen the regulation of the pharmaceutical sector in Argentina. The agency is responsible for overseeing all aspects of the drug lifecycle, from research and development to manufacturing, distribution, and post-market surveillance. ANMAT’s function is crucial for protecting public health and ensuring that Argentinians have access to safe and effective medications.
The agency’s focus on good distribution practices reflects a growing international emphasis on supply chain integrity. Counterfeit and substandard medications pose a significant threat to global health, and robust regulatory frameworks are essential for mitigating this risk. ANMAT’s actions demonstrate its commitment to aligning with international standards and safeguarding the health of the Argentine population.
ANMAT will continue to monitor the situation and provide updates as more information becomes available. The agency encourages stakeholders to consult the Official Gazette and its website for the latest information regarding pharmaceutical regulations and enforcement actions. The next official update regarding the reinstatement of licenses is expected within 30 days, pending the completion of inspections and audits.
Have your say: What are your thoughts on ANMAT’s recent actions? Share your comments below and assist us continue to provide comprehensive coverage of important health and regulatory news.
